

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**


**LISTING OF CLAIMS:**

**1. (canceled).**

**2. (canceled).**

**3.-67. (canceled).**

**68. (previously presented)** A compound represented by the following formula (I-B):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) a halogen atom, (4) trihalomethyl, (5) Cyc1, (6) -OR<sup>6</sup>, or (7) C1-8 alkyl substituted with -OR<sup>6</sup> or Cyc1;

R<sup>6</sup> represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) Cyc1, (5) methyl substituted with 1 to 3 halogen, or (6) C1-8 alkyl substituted with Cyc1;

Cycl represents a C3-10 monocyclic or bicyclic carbocyclic group;

G represents a bond,

K and M each independently represents (1) a bond, (2) C1-8 alkylenes, or (3) C2-8 alkenylene;

L represents a bond or an oxygen atom;

Ring A represents a C3-10 monocyclic or bicyclic carbocyclic group;

Ring B represents a C3-10 monocyclic or bicyclic carbocyclic group or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring D represents a C3-10 monocyclic carbocyclic group or a three- to ten-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring E represents a C3-7 monocyclic carbocyclic group;

p, q, r and s each independently represents 0 or an integer of from 1 to 3,

in which R<sup>1</sup>'s are the same or different when p represents 2 or more; R<sup>2</sup>'s are the same or different when q represents 2 or more; R<sup>3</sup>'s are the same or different when r represents 2 or more; and R<sup>4</sup>'s are the same or different when s represents 2 or more, respectively;

t represents 0 or 1; and

R<sup>5</sup> represents (1) a hydrogen atom or (2) C1-8 alkyl, or a salt thereof.

**69. (currently amended)** A pharmaceutical composition comprising the compound according to claim 68, ~~or a salt thereof or a prodrug thereof~~ and a pharmaceutically acceptable carrier.

**70. (previously presented)** The pharmaceutical composition according to claim 69, which is an LPA receptor antagonist.

**71. (previously presented)** The pharmaceutical composition according to claim 70, wherein the LPA receptor is EDG-2 receptor.

**72. (currently amended)** The pharmaceutical composition according to claim 71, which is an agent for ~~prevention and/or~~ treatment for urinary system disease.

**73. (canceled).**

**74. (currently amended)** A method for ~~prevention and/or~~ treatment of diseases referred from EDG-2, which comprises administering an effective amount of the compound according to claim 68, ~~or a salt thereof or a prodrug thereof~~ to a mammal.

**75. (currently amended):** The method for ~~prevention and/or~~ treatment according to claim 74, wherein the disease referred from EDG-2 is urinary system disease.

**Claims 76-80. (canceled).**